Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIK2 | Q9H0K1 | 13/20 | 1.00 |
| ▸ | SIK3 | Q9Y2K2 | 13/20 | 1.00 |
| ▸ | ABL1 | P00519 | 12/20 | 1.00 |
| ▸ | SIK1 | P57059 | 11/20 | 1.00 |
| ▸ | SRC | P12931 | 5/20 | 0.79 |
| ▸ | PKMYT1 | Q99640 | 3/20 | 0.77 |
| ▸ | EPHB6 | O15197 | 2/20 | 0.77 |
| ▸ | EGFR | P00533 | 2/20 | 0.77 |
| ▸ | LCK | P06239 | 2/20 | 0.77 |
| ▸ | FYN | P06241 | 2/20 | 0.77 |
| ▸ | CSF1R | P07333 | 2/20 | 0.77 |
| ▸ | YES1 | P07947 | 2/20 | 0.77 |
| ▸ | LYN | P07948 | 2/20 | 0.77 |
| ▸ | RET | P07949 | 2/20 | 0.77 |
| ▸ | HCK | P08631 | 2/20 | 0.77 |
| ▸ | KIT | P10721 | 2/20 | 0.77 |
| ▸ | BCR | P11274 | 2/20 | 0.77 |
| ▸ | BRAF | P15056 | 2/20 | 0.77 |
| ▸ | EPHA1 | P21709 | 2/20 | 0.77 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21875057 | 0.94 | ABL1 (1.00) | SIK2SIK3ABL1SIK1SRC | |
| SCHEMBL13378598 | 0.92 | ABL1 (0.89) | SIK2SIK3ABL1SIK1SRC | |
| SCHEMBL31634945 | 0.92 | ABL1 (0.89) | SIK2SIK3ABL1SIK1SRC | |
| SCHEMBL28519145 | 0.92 | SIK2 (0.85) | SIK2SIK3ABL1SIK1SRC | |
| SCHEMBL23987823 | 0.90 | SIK2 (0.87) | SIK2SIK3ABL1SIK1SRC | |
| SCHEMBL31307342 | 0.90 | SIK2 (0.87) | SIK2SIK3ABL1SIK1SRC | |
| SCHEMBL21875006 | 0.89 | SIK2 (1.00) | SIK2SIK3ABL1SIK1SRC | |
| SCHEMBL30152057 | 0.89 | SIK2 (1.00) | SIK2SIK3ABL1SIK1SRC | |
| SCHEMBL21875015 | 0.88 | SIK2 (1.00) | SIK2SIK3ABL1SIK1SRC | |
| SCHEMBL31052590 | 0.88 | SIK2 (0.80) | SIK2SIK3ABL1SIK1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3643713-B1 | HETEROCYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2025-07-30 | — | — | EP | disclosed |
| US-20250101015-A1 | HETEROCYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2025-03-27 | — | — | US | disclosed |
| US-20250084076-A1 | HETEROCYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2025-03-13 | — | — | US | disclosed |
| US-12172993-B2 | Heterocyclic kinase inhibitors and uses thereof | IOMX THERAPEUTICS AG (DE) | 2024-12-24 | — | — | US | disclosed |
| US-20230348453-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2023-11-02 | — | — | US | disclosed |
| US-20230348453-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2023-11-02 | — | — | US | disclosed |
| EP-4139305-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | iOmx Therapeutics AG (DE) | 2023-03-01 | — | — | EP | disclosed |
| CN-115667255-A | Halogenated heteroaryl and other heterocyclic kinase inhibitors and uses thereof | 艾欧麦克斯治疗股份公司 | 2023-01-31 | — | — | CN | disclosed |
| US-20210387982-A1 | HETEROCYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2021-12-16 | — | — | US | disclosed |
| WO-2021214117-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2021-10-28 | — | — | WO | disclosed |
| EP-3901151-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | iOmx Therapeutics AG (DE) | 2021-10-27 | — | — | EP | disclosed |
| CN-112955447-A | Heterocyclic kinase inhibitors and uses thereof | 艾欧麦克斯治疗股份公司 | 2021-06-11 | — | — | CN | disclosed |
| EP-3643713-A1 | HETEROCYCLIC KINASE INHIBITORS AND USES THEREOF | iOmx Therapeutics AG (DE) | 2020-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12172993-B2 | Heterocyclic kinase inhibitors and uses thereof | LCK, SRC, CILK1 | SIK2 25/4885SIK3 46/4885ABL1 8/4885 |
| US-20210387982-A1 | HETEROCYCLIC KINASE INHIBITORS AND USES THEREOF | LCK, SRC, CILK1 | SIK2 25/4885SIK3 46/4885ABL1 8/4885 |
| US-20250101015-A1 | HETEROCYCLIC KINASE INHIBITORS AND USES THEREOF | LCK, SRC, CILK1 | SIK2 25/4885SIK3 46/4885ABL1 8/4885 |
| US-20230348453-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | ABL1, PRKDC, PRKACA | SIK2 154/4885SIK3 180/4885ABL1 1/4885 |
| US-20250084076-A1 | HETEROCYCLIC KINASE INHIBITORS AND USES THEREOF | LCK, SRC, CILK1 | SIK2 25/4885SIK3 46/4885ABL1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.